NPRA Banner

               
Product Search   QUEST3+ System   Enquiries   Sitemap  

Crysvita® (Burosumab): Risk of Severe Hypercalcaemia

Bintang tidak aktifBintang tidak aktifBintang tidak aktifBintang tidak aktifBintang tidak aktif
 

Important notice: Direct Healthcare Professional Communication (DHPC) letters are primarily intended for healthcare professionals. Patients/caregivers who have questions or concerns about the safety information presented are advised to consult their doctor or pharmacist.

 

Direct Healthcare Professional Communication (DHPC) letters are issued by pharmaceutical companies to inform healthcare professionals about important safety information concerning medicinal products, and recommended measures to minimise the risks. DHPCs aim to support healthcare professionals in making informed decisions and ensuring the safe and appropriate use of medicines.


This webpage features only DHPCs evaluated by the Pharmacovigilance Section, NPRA, that communicate newly identified or emerging safety issues, or important safety updates issued as part of additional risk minimisation measures, requiring the attention or action of healthcare professionals. 

 

For Healthcare Professionals only

DKSH Malaysia Sdn Bhd. has issued a DHPC letter related to a safety issue. 

Are you a healthcare professional?

Yes, open the document

No, return to homepage

 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Khamis 29 Oktober 2026, 11:29:48.

Search